Etzer Darout
Stock Analyst at BMO Capital
(1.33)
# 1747
Out of 5,249 analysts
119
Total ratings
37.66%
Success rate
10.72%
Average return
Main Sectors:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
IGM Biosciences | Downgrades: Market Perform | 21 2 | 1.71 | 16.96% | 2 | Jan 10, 2025 | |
Exelixis | Downgrades: Market Perform | 36 40 | 33.8 | 18.34% | 3 | Dec 20, 2024 | |
Q32 Bio | Maintains: Outperform | 64 22 | 3.36 | 554.76% | 2 | Dec 12, 2024 | |
Tourmaline Bio | Initiates Coverage On: Outperform | 50 | 17.25 | 189.86% | 1 | Dec 6, 2024 | |
Protagonist Therapeu... | Initiates Coverage On: Outperform | 62 | 37.78 | 64.11% | 1 | Dec 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 35 | 19.89 | 75.97% | 1 | Dec 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 55 | 44.54 | 23.48% | 1 | Dec 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 63 | 6.07 | 937.89% | 1 | Dec 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 90 88 | 18.23 | 382.72% | 2 | Nov 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 28 27 | 5.54 | 387.36% | 7 | Nov 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 132 134 | 82.42 | 62.58% | 6 | Nov 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 32 34 | 20.97 | 62.14% | 5 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 46 48 | 21.28 | 125.56% | 3 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 118 120 | 99.71 | 20.35% | 3 | Oct 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 34 38 | 45.4 | -16.3% | 3 | Oct 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 19 26 | 4.67 | 456.75% | 4 | Sep 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 26 25 | 6.34 | 294.32% | 6 | Aug 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 8 5 | 3.16 | 58.23% | 9 | Aug 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 20 20 | 3.77 | 430.5% | 3 | Aug 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 84 91 | 41.13 | 121.25% | 5 | Jun 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 7 6 | 1.34 | 347.76% | 7 | May 10, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 4 4 | 0.86 | 317.44% | 10 | May 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 123 122 | 120.79 | 1% | 3 | May 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 80 82 | 68.61 | 19.52% | 4 | Apr 26, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 31 | n/a | n/a | 4 | Dec 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 12 | 2.49 | 381.93% | 2 | Sep 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 20 19 | 4.39 | 332.8% | 2 | Apr 25, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 179 229 | n/a | n/a | 4 | Mar 14, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 170 | 273.22 | -37.78% | 2 | Feb 3, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 84 | 8.34 | 907.19% | 1 | Jul 12, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 60 | n/a | n/a | 1 | May 18, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 38 | n/a | n/a | 5 | Mar 9, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 54 | 25.44 | 112.26% | 1 | Feb 26, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Sep 22, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 27 38 | 48.95 | -22.37% | 2 | Sep 9, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 54 52 | 2.55 | 1939.22% | 1 | Mar 28, 2018 |